We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | NASDAQ:FOLD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.12 | -1.15% | 10.30 | 10.19 | 11.99 | 10.79 | 10.36 | 10.74 | 1,360,422 | 05:00:01 |
By Chris Wack
Trading in shares of Amicus Therapeutics was halted at $12.88 as the Food and Drug Administration approved Pombiliti + Opfolda 65mg capsules for adults living with late-onset Pompe disease, and who aren't improving on their current enzyme replacement therapy.
The stock hit its 52-week high of $14.10 on Aug. 9, and is up 20% in the past 12 months.
Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase.
Pombiliti is a recombinant human enzyme naturally expressed with high levels of bis-Mannose 6-Phosphate, designed for increased uptake into muscle cells. Opfolda is an enzyme stabilizer designed to stabilize the enzyme in the blood.
The FDA approval was based on clinical data observed from a Phase 3 pivotal study, the only trial in late-onset Pompe disease to study ERT-experienced participants in a controlled setting.
Amicus Therapeutics will launch Pombiliti + Opfolda immediately in the U.S. The FDA previously granted Breakthrough Therapy designation for Pombiliti + Opfolda. It has also been approved for the treatment of adults with late-onset Pompe disease in the E.U. and the U.K.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 28, 2023 11:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Amicus Therapeutics Chart |
1 Month Amicus Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions